Journal of Shandong University (Health Sciences) ›› 2025, Vol. 63 ›› Issue (1): 99-107.doi: 10.6040/j.issn.1671-7554.0.2024.0935

• Clinical Research • Previous Articles    

Causal relationship between low grade serous ovarian cancer and breast cancer analyzed by Mendelian randomization

YUAN Zonghuai, PAN Guangye, CHI Yuemei, AN Chuanguo, ZHANG Yonggang   

  1. Department of General Surgery, Peoples Hospital of Rizhao, Rizhao 276800, Shandong, China
  • Published:2025-02-20

Abstract: Objective To explore the causal relationship between low grade serous ovarian cancer(LGSOC)and breast cancer(BC). Methods The study employed a bidirectional two sample Mendelian randomization(MR)method, and utilized publicly available genetic data from genome-wide association studies in European populations, with single nucleotide polymorphisms(SNPs)as instrumental variables. The forward study used LGSOC as the exposure variable and BC as the outcome, while the reverse study used BC as the exposure variable and LGSOC as the outcome. In addition, subgroup analysis was conducted on four molecular subtypes of BC. Inverse variance weighted(IVW), MR Egger regression, weighted median, weighted model, and simple model were used to study the causal relationship between LGSOC and BC. The Cochrans Q test was used for heterogeneity of instrumental variables. The MR Egger intercept method was used to test horizontal pleiotropy. Results The positive study included 19 SNPs, and MR analysis showed a positive causal relationship between LGSOC and increased risk of BC(IVW: OR=1.05, 95%CI: 1.01-1.08, P=0.01). Subgroup analysis showed that LGSOC may have a causal relationship with estrogen receptor positive(ER+)BC(P=0.07). The reverse study included 95 SNPs, and the MR analysis results showed that there was no causal relationship between BC and increased risk of LGSOC(P>0.05). No significant heterogeneity or horizontal pleiotropy was found in both heterogeneity and pleiotropy tests(P>0.05). Conclusion There is a positive causal relationship between LGSOC and increased risk of BC in Europeans, which may increase the risk of ER+BC. The causal relationship between BC and increased risk of LGSOC is not supported.

Key words: Low grade serous ovarian cancer, Breast cancer, Molecular subtype, Mendelian randomization, Causal relationship

CLC Number: 

  • R737
[1] Zwimpfer TA, Tal O, Geissler F, et al. Low grade serous ovarian cancer-a rare disease with increasing therapeutic options[J]. Cancer Treat Rev, 2023, 112: 102497. doi: 10.1016/j.ctrv.2022.102497.
[2] Montero-Macías R, Segura-Sampedro JJ, Rigolet R, et al. The role of systematic lymphadenectomy in low-grade serous ovarian cancer: a systematic review and Meta-analysis[J]. Cancers(Basel), 2024, 16(5): 955. doi: 10.3390/cancers16050955.
[3] Kathleen IP, Karla JC, Marta LF, et al. High-throughput drug screening identifes novel therapeutics for low grade serous ovarian carcinoma[J]. Sci Data, 2024, 11(1):1024. doi: 10.1038/s41597-024-03869-x.
[4] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263.
[5] Bao R, Qu H, Li B, et al. Knowledge mapping of immunotherapy for breast cancer: a bibliometric analysis from 2013 to 2022[J]. Hum Vaccin Immunother, 2024, 20(1): 2335728. doi: 10.1080/21645515.2024.2335728.
[6] Öfverholm A, Törngren T, Rosén A, et al. Extended genetic analysis and tumor Characteristics in over 4600 women with suspected hereditary breast and ovarian cancer[J]. BMC Cancer, 2023, 23(1): 738. doi: 10.1186/s12885-023-11229-y.
[7] Innella G, GodinoL, Erini G, et al. Factors predicting BRCA1/2 pathogenic variants in patients with ovarian cancer: a systematic review with meta-analysis[J]. J Clin Pathol, 2023, 76(8): 510-517.
[8] Ottenbourgs T, Van NE. Novel endocrine therapeutic opportunities for estrogen receptor-positive ovarian cancer-what can we learn from breast cancer?[J]. Cancers(Basel), 2024, 16(10): 1862. doi: 10.3390/cancers16101862.
[9] Smylie J, Rotondi MA, Filipenko S, et al. Randomized controlled trial demonstrates novel tools to assess patient outcomes of Indigenous cultural safety training[J]. BMC Med, 2024, 22(1): 3. doi: 10.1186/s12916-023-03193-y.
[10] Birney E. Mendelian randomization[J]. Cold Spring Harb Perspect Med, 2022, 12(4): a041302. doi: 10.1101/cshperspect.a041302.
[11] Fang A, Zhao Y, Yang P, et al. Vitamin D and human health: evidence from Mendelian randomization studies[J]. Eur J Epidemiol, 2024, 39(5): 467-490.
[12] Davies NM, Holmes MV, Davey SG, et al. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians[J]. BMJ, 2018, 362: k601. doi: 10.1136/bmj.k601.
[13] 李舒冉, 孙静, 孙绮悦, 等. 便秘与肺炎因果关系的双向孟德尔随机化分析[J].中国实验方剂学杂志, 2024, 30(23): 224-229. LI Shuran, SUN Jing, SUN Qiyue, et al. Bidirectional Mendelian randomization analysis of causal relationship between constipation and pneumonia[J]. Chinese Journal of Experimental Traditional Medical Formulae, 2024, 30(23): 224-229.
[14] Chen LL, Yang HQ, Li HT, et al. Insights into modifiable risk factors of cholelithiasis: a Mendelian randomization study[J]. Hepatology, 2022, 75(4): 785-796.
[15] Pan SY, Zhang ZQ, Pang WY, et al. The causal relationship between bacterial pneumonia and diabetes: a two-sample mendelian randomization study[J]. Islets, 2024, 16(1): 2291885. doi: 10.1080/19382014.2023.2291885.
[16] Cheng ZJ, Gao L, Huang P, et al. Genetic causal association between rheumatoid arthritis and periodontitis: a bidirectional two-sample Mendelian randomization analysis[J]. Clin Oral Investig, 2024, 28(1): 107. doi: 10.1007/s00784-024-05512-w.
[17] Bowden J, Holmes MV. Meta-analysis and Mendelian randomization: a review[J]. Res Synth Methods, 2019, 10(4): 486-496.
[18] Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method[J]. Eur J Epidemiol, 2017, 32(5): 377-389.
[19] Bowden J, Davey SG, Haycock PC, et al. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator[J]. Genet Epidemiol, 2016, 40(4): 304-314.
[20] Yin KJ, Huang JX, Wang P, et al. No genetic causal association between periodontitis and arthritis: a bidirectional twosample Mendelian randomization analysis[J]. Front Immunol, 2022, 13: 808832. doi: 10.3389/fimmu.2022.808832.
[21] Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports systematic causal inference across the human phenome[J]. Elife, 2018, 7: e34408. doi: 10.7554/eLife.34408.
[22] Shu MJ, Li JR, Zhu YC, et al. Migraine and ischemic stroke: a mendelian randomization study[J]. Neurol Ther, 2022, 11(1): 237-246.
[23] Jin Y, Yu X, Li J, et al. Causal effects and immune cell mediators between prescription analgesic use and risk of infectious diseases: a Mendelian randomization study[J]. Front Immunol, 2023, 14: 1319127. doi: 10.3389/fimmu.2023.1319127.
[24] Babaier A, Mal H, Alselwi W, et al. Low-grade serous carcinoma of the ovary: the current status[J]. Diagnostics(Basel), 2022, 12(2): 458. doi: 10.3390/diagnostics12020458.
[25] Si SH, Li JQ, Marlvin AT, et al. Identifying causality, genetic correlation, priority and pathways of large-scale complex exposures of breast and ovarian cancers[J]. Br J Cancer, 2021, 125(11): 1570-1581.
[26] Marisa AV, Molly SD, Diana LU, et al. Is low-grade serous ovarian cancer part of the tumor spectrum of hereditary breast and ovarian cancer?[J]. Gynecol Oncol, 2011, 120(2): 229-232.
[27] Shalaka J, Sridevi MN, Shylasree TS, et al. Synchronous and metachronous breast and ovarian cancers: experience from a single tertiary care cancer centre in India[J]. Indian J Surg Oncol, 2023, 14(4): 809-821.
[28] Catherine SJ, Abigail F, Rodrigo A, et al. Breast cancer surveillance following ovarian cancer in BRCA mutation carriers[J]. Gynecol Oncol, 2022, 164(1): 202-207.
[29] Perrone C, Angioli R, Luvero D, et al. Targeting BRAF pathway in low-grade serous ovarian cancer[J]. J Gynecol Oncol, 2024, 35(4): e104. doi: 10.3802/jgo.2024.35.e104.
[30] Gershenson DM, Sun CC, Westin SN, et al. The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes[J]. Gynecol Oncol, 2022, 165(3): 560-567.
[31] 张娜娜,赵一鸣,刘新敏,等.基于两样本孟德尔随机化探索子宫肌瘤与乳腺癌的因果关系[J].山东大学学报(医学版), 2023, 61(8): 86-93. ZHANG Nana, ZHAO Yiming, LIU Xinmin, et al.Causal relationgship between uterine leiomyomas and breast cancer:a two-sample Mendelian randomization study[J]. Journal of Shandog University(Health Sciences), 2023, 61(8): 86-93.
[32] Kim YN, Chung YS, Park E, et al. Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer[J]. Sci Rep, 2024, 14(1): 7992. doi: 10.1038/s41598-024-57515-y.
[33] 中国抗癌协会肿瘤标志物专业委员会, 上海市抗癌协会肿瘤标志物专业委员会. 基于中国人群的BRCA胚系突变筛查专家共识(2024年版)[J]. 中国癌症杂志, 2024, 34(2): 220-238. China Anti-Cancer Association Tumor Biomarker Professional Committee, Shanghai Anti-Cancer Association Tumor Biomarker Professional Committee. Expert consensus on population-based BRCA germline mutation screening in China(2024 edition)[J]. China Oncology, 2024, 34(2): 220-238.
[34] Emanuela DA, Iñigo E, Lara F, et al. Ovarian high-grade serous carcinoma with transitional-like(SET)morphology: a homologous recombination-deficient tumor[J]. Hum Pathol, 2023, 141: 15-21. doi: 10.1016/j.humpath.2023.08.010.
[1] YU Zhigang, ZHENG Chao. Current status, challenges and innovative approaches of multidisciplinary treatment for breast cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(1): 1-9.
[2] . Shandong Province expert consensus on multidisciplinary treatment of breast cancer(2024 edition) [J]. Journal of Shandong University (Health Sciences), 2025, 63(1): 10-16.
[3] CHENG Yueqi, WANG Fei, YU Lixiang, ZHENG Chao, YU Zhigang. Progress in the study of trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients [J]. Journal of Shandong University (Health Sciences), 2025, 63(1): 17-24.
[4] WANG Min, LI Xiping, TAN Jun, QIU Mei, HOU Zeyu, TIAN Ying, LUO Hongying, FAN Chaowen, QI Ling, YU Qi, XIE Wei. Lentivirus vector-mediated Gag-Caspase-8 induces apoptosis and S-phase arrest in triple-negative breast cancer primary cells [J]. Journal of Shandong University (Health Sciences), 2025, 63(1): 25-34.
[5] ZHANG Jie, ZHANG Fangfang, WANG Jingnan, LI Zeyu, SONG Ying, LI Na. Expression of circ_0000144 in breast cancer and its effect on the proliferation, migration and invasion ability of breast cancer cells [J]. Journal of Shandong University (Health Sciences), 2025, 63(1): 35-42.
[6] SONG Yawen, GUO Liantao, KONG Deguang, SUN Shengrong. VTCN1 causes poor prognosis and endocrine therapy resistance in HR+ breast cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(1): 43-59.
[7] LIU Jingjing, PANG Jing, ZHAO Xiaodan, LIN Xin, FU Min, CHEN Jingjing. Machine learning model based on mammography and DCE-MRI to predict pathological complete response after neoadjuvant therapy in breast cancer: a dual center research [J]. Journal of Shandong University (Health Sciences), 2025, 63(1): 60-72.
[8] SUN Jing, YANG Ruimin, WANG Cong, ZHANG Yue, LUO Bing. Combined models based on preoperative ultrasound, inflammatory indicators and ultrasound radiomics for predicting axillary lymph node metastasis of breast cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(1): 73-80.
[9] LI Yong, CUI Shujun, YANG Fei, ZHANG Fan, YIN Xiaoxia. Enhanced MRI-based subregional radiomics model can predict pathological complete response after neoadjuvant chemotherapy in breast cancer patients [J]. Journal of Shandong University (Health Sciences), 2025, 63(1): 81-89.
[10] LIU Xiangrong, ZHANG Xinsheng, YANG Jinran, YANG Xueyan, LIU Zhao, LIU Yinghua. Association of the ratio of ω-6/ω-3 polyunsaturated fatty acids with various tumor types risk: a systematic review and Meta-analysis [J]. Journal of Shandong University (Health Sciences), 2024, 62(8): 34-48.
[11] ZHANG Zhan, LI Jianfeng, LI Yanling, WANG Bowen, ANGWEN Chenglinlongzhu, WANG Xin, ZHANG Xiaoming, XIE Ping. Mendelian randomization analysis of causality between dietary factors and preeclampsia [J]. Journal of Shandong University (Health Sciences), 2024, 62(8): 59-66.
[12] FENG Yue, YU Yifan, WU Sijia, LI Hongkai, XUE Fuzhong. Mendelian randomization study of visceral adipose tissue and lung diseases [J]. Journal of Shandong University (Health Sciences), 2024, 62(7): 48-55.
[13] WU Tong, YANG Jingyu, LIN Dang, XU Wanru, ZENG Yujun. Genetic association of lipids and lipid-lowering drugs with chronic obstructive pulmonary disease based on Mendelian randomization [J]. Journal of Shandong University (Health Sciences), 2024, 62(5): 54-63.
[14] WU Fei, LI Qingli, XIAO Zhenwei. Causal association between cytokines and chronic kidney disease based on Mendelian randomization [J]. Journal of Shandong University (Health Sciences), 2024, 62(11): 85-95.
[15] ZHANG Nana, ZHAO Yiming, LIU Xinmin. Causal relationship between uterine leiomyomas and breast cancer: a two-sample Mendelian randomization study [J]. Journal of Shandong University (Health Sciences), 2023, 61(8): 86-93.
Viewed
Full text
94
HTML PDF
Just accepted Online first Issue Just accepted Online first Issue
0 0 0 0 0 94

  From local
  Times 94
  Rate 100%

Abstract
276
Just accepted Online first Issue
0 0 276
  From Others local
  Times 274 2
  Rate 99% 1%

Cited

Web of Science  Crossref   ScienceDirect  Search for Citations in Google Scholar >>
 
This page requires you have already subscribed to WoS.
  Shared   
  Discussed   
No Suggested Reading articles found!